Observational Study of Breast Cancer Tissue and Blood Samples

This observational study, NCT01000883, is collecting samples of tumor tissue and blood from people with breast cancer. Researchers want to understand how breast cancer behaves and how it responds to treatment by studying these samples in the lab. They will be looking for changes in DNA and identifying markers (biomarkers) that might be related to cancer. The study is open to adults aged 18 and older who have suspected or known breast cancer that can be safely biopsied. The main goal is to create a collection (biorepository) of these samples for current and future research. The study's current status is unclear, and it aims to enroll about 500 participants.

Study design
This is an observational study aiming to enroll about 500 participants. It is not testing a specific treatment but rather collecting information and samples.
What's involved
You would undergo a core biopsy (a procedure to take a small tissue sample) and have blood drawn at diagnosis, between chemotherapy treatments, and before definitive surgery.
Compensation
Not stated in the trial record.
Follow-up
The study aims to collect clinical data including long-term follow-up, but a specific duration is not provided.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01000883

Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

Recruiting
Not specifiedAges 18+Observational
UNC Lineberger Comprehensive Cancer Center
~10,000 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:biologic sample preservation procedurelaboratory biomarker analysisbiopsy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Generation of a biorepository for current and future correlative research studies
Measured over Diagnosis, between treatments,7-14 days after start of treatment and at time of definitive therapy
Breast Cancer
1 sites across 1 states
North Carolina1
  • Lisa A. Carey, MD · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

  • Generation of a biorepository for current and future correlative research studiesDiagnosis, between treatments,7-14 days after start of treatment and at time of definitive therapy